Pharma-provided patient support programs (PSPs) represent an emerging industry trend, and payers have taken notice. In a recent survey conducted in France and the United Kingdom, Observia asked payers for their opinions on PSPs and their importance when included in a product evaluation. The survey reveals that:
- Payers have a favorable opinion of PSPs.
- PSPs are increasingly included as part of a product evaluation.
- The inclusion of a PSP can affect the decision in before product evaluation.
- Payers expect that PSP results/outcomes, which accompany a product evaluation request, will become more common.
These results should come as good news to brand managers and market access teams. In an era when pharma is having to work harder to justify its pricing to payers, PSPs can be used as an opportunity to demonstrate value. PSP pioneers and patient-centricity champions should also rejoice, as the results further justify program investment. (...)
The survey was realized in France and in the UK and 30 payers where asked about their opinion on PSPs.
Recevoir nos news
Tweets by Observia_Esante
Nous suivre